CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Tim ...

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft (NASDAQ:HOVR), doing business as Horizon Aircraft ("Horizon Aircraft" or the "Company"), the advanced aerospace engineering company and developer of eVTOL (electric Vertical Take-Off and Landing) aircraft, publishes new global research* that indicates fund managers that invest primarily in small-cap and micro-cap stocks believe there will be an increased level of exposure to small and micro-caps from both institutional and retail investors over ...

Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been awarded a $1.9M two-year contract from the U.S. Air Force (USAF) to support the continued development of a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer for military and civilian applications. Michael Feldschuh, Daxor's President and CEO, highlighted the significance of this ...

Enhances Focus on Returning Capital to Shareholders With Updated Dividend Policy Declares Cash Dividend of $0.25 Per Share reflecting strong financial results | --- | --- | --- | --- | --- | --- | |-----------------------------------------|---------|---------|-------|---------|---------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Highlights (in million USD, except EPS) | Q2 2024 | Q2 2023 | | 6M 2024 | 6M 2023 | | | | | | | | | Net Revenues | $43.1 | $28.3 | $81.4 | | $46.4 | | ...

文章核心观点 - 公司宣布派发每股0.04美元的定期现金股利,将于2024年9月2日支付给2024年8月19日登记在册的股东[1] 公司概况 - 公司主要从事海洋和重型非公路动力传动设备的设计、制造和销售[2] - 产品包括海洋变速箱、方位驱动装置、表面驱动装置、螺旋桨和船舶管理系统,以及动力换挡变速箱、液压扭矩转换器、动力输出装置、工业离合器和控制系统[2] - 公司的客户主要集中在休闲船艇、商业和军事海事市场,以及能源和自然资源、政府和工业市场[2] - 公司通过直销团队和分销网络在全球范围内开展业务[2]

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzh ...

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing ope ...

Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers (BTC) Approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting in patients with Biliary Tract Cancer BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company deve ...

CUPERTINO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- -Similar patent has also been granted in Japan -Brilaroxazine has received Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (IPF) Cupertino, Calif., August 6, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, ...

文章核心观点 - 该文章报道了2024年度Altair Enlighten Award获奖名单,这是一个专注于汽车行业可持续性和轻量化创新的重要奖项 [1][2][4][5][6] - 获奖企业包括杜邦、宝马、陶氏、丰田、通用等行业领先企业,他们在减碳、节能、材料再利用等方面取得了重大突破 [3][7][10][13][17][23][27] - 获奖技术涵盖了可持续产品、可持续生产工艺、模块轻量化、关键使能技术等多个领域,体现了行业在可持续发展方面的不同创新 [7][10][13][17][23] 可持续产品 - 杜邦的BETAMATE广谱固化粘接技术可以在较低温度下固化,从而减少车身制造过程中的能耗和温室气体排放 [7][8] - 普利司通的Turanza EV轮胎采用50%可再生和回收材料制造,并采用ENLITEN技术优化性能和延长使用寿命 [8][9] 可持续生产工艺 - 宝马M公司等企业开发了基于循环设计理念和可再生材料的BMW M Visionary Materials座椅 [10][11] - 丰田和PPG开发的EPIC200X电泳涂料可以大幅减少CO2排放、能耗和用水量 [11][12] 模块轻量化 - 赛恩斯科和通用汽车开发了一种高性能热塑性电池模块结构,相比铝材可减重37%、降低25%成本 [13][14] - 丰田等企业开发了30%更轻的塑料复合材料二排座椅结构 [15][16] 关键使能技术 - 康波特公司利用天然纤维复合材料开发了可用于车身、内饰等多种汽车部件的可持续高性能结构 [17][18] - 帝人公司开发了全自动预成型工艺,可大幅提高碳纤维预制件的生产效率 [19][20] 未来轻量化 - WEAV3D等企业开发了一种成本更低、重量更轻的复合材料车身结构 [23][24][25] - 卡索利亚公司开发了50%更轻的碳纤维复合材料悬架弹簧 [25][26] 负责任的人工智能 - 陶氏公司开发了一种基于人工智能的可持续聚氨酯解决方案,大幅降低了有害物质排放 [27][28]